Welcome to Browse Page of Biomarker

This page shows the result of browsing biomarker from different fieldss.For more information see HELP page.

The total number entries retrieved from this search are 452
Please click on Biomarker_ID to view detailed information.
Note: Potential Biomarker with * indicates these signatures are candidate biomarkers extracted from experiments on mice, rat or cell lines and they are not validated on human patients'cohort.
Biomarker IDBiomarkerBiomoleculeSubjectRegulationBiomarker's typeExperimentLevel of significanceSourcePMID
2092DLC1RNAsHumanDownregulated in HCC PrognosticCancer v/s Normal; predict survival of patients p < 0.05Tissue26846339
2102CPERNAsHumanCPE expression level was also significantly correlated with the tumor recurrence for both stage i.e. Stage-I and Stage-II PrognosticRecurrence between stage-I v/s stage-II p < 0.01Tissue26803519
2103AFP-L3ProteinHumanUpregulated in AFP-negative HCC patients DiagnosticNormal vs HCC p < 0.01Tissue26770061
2104GP73ProteinHumanUpregulated in AFP-negative HCC patients DiagnosticNormal vs HCC p < 0.01Tissue26770061
2105AFP-L3, GP73 (combined)ProteinHumanUpregulated in AFP-negative HCC patients DiagnosticNormal vs HCC p < 0.01Tissue26770061
2106TOPO2ProteinHumanDownregulated in nucleolus of HCC DiagnosticNormal vs HCC NATissue26722553
2108ABCC3ProteinRat and Humanoverexpressed in hepatocellular carcinoma Potential Diagnostic *Normal vs HCC p < 0.01Tissue26337276
2111qEASLMethod (Others)HumanNA Predictive TACE responder v/s TACE non-responder p < 0.05Tissue26131913
2112vRECISTMethod (Others)HumanNA Predictive TACE responder v/s TACE non-responder p < 0.05Tissue26131913
2118HNF4A, RelAmiRNAHumanupregulated in hepatoma cells PrognosticL-HNF4α group v/s hig-HNF4α group; associated with survival of patients p < 0.05Tissue24752868
2119KIAA1114ProteinHuman and Mice cell linesKIAA1114 is overexpressed in human liver cancer cell lines Potential Diagnostic *Normal cell line vs HCC cell line p < 0.05Tissue24713374
2127DNA hypomethylated regions of GPM6BEpigenetic (Others)Humanhypomethylated and Upregulated level in HCC DiagnosticCancer v/s Normal p < 0.01Tissue23950870
2128DNA hypomethylated regions of MAGEA12Epigenetic (Others)Humanhypomethylated and Upregulated level in HCC DiagnosticCancer v/s Normal p < 0.01Tissue23950870
2129DNA hypomethylated regions of FCRL1Epigenetic (Others)Humanhypomethylated and Upregulated level in HCC DiagnosticInvasive HCC v/s non-invasive HCC p < 0.01Tissue23950870
2132CYP3A4ProteinHumanUpregulated in in hepatitis B virus-associated liver cirrhosis and stage I hepatocellular carcinoma, PrognosticHCC vs adjacent non-tumor and stageII v/s stage-III; predict early stage p < 0.05Tissue and Cells 23891548
2135XPO4ProteinHumanUpregulated in paracancerous than in cancerous liver tissue PrognosticNormal vs HCC; predict survival of patients p < 0.0001Tissue23251252
2136TGFβ1ProteinHumanUpregulated in paracancerous than in cancerous liver tissue PrognosticNormal vs HCC; predict survival of patients p < 0.0001Tissue23251252
2137elF5A2ProteinHumanUpregulated in paracancerous than in cancerous liver tissue PrognosticNormal vs HCC; predict survival of patients p < 0.0001Tissue23251252
2138ANGPTL4ProteinHumanUpregulated in paracancerous than in cancerous liver tissue PrognosticNormal vs HCC; predict survival of patients p < 0.0001Tissue23251252
2139C3ProteinMale Wistar ratsUpregulated at very early stage in HCC Potential Diagnostic *Normal vs HCC p < 0.05Tissue23245919
2140miR-18b*miRNAHumanDownregulated in the HCC v/s non-tumor (with fold change 0.21) DiagnosticNormal v/s HCC/HCV/HBV p < 0.001Tissue23205106
2141miR-296-5pmiRNAHumanDownregulated in the HCC v/s non-tumor (with fold change 0.16) DiagnosticNormal v/s HCC/HCV/HBV p < 0.001Tissue23205106
2142miR-557miRNAHumanDownregulated in the HCC v/s non-tumor (with fold change 0.29) DiagnosticNormal v/s HCC/HCV/HBV p < 0.01Tissue23205106
2143miR-581miRNAHumanDownregulated in the HCC v/s non-tumor (with fold change 0.10) DiagnosticNormal v/s HCC/HCV/HBV p < 0.01Tissue23205106
2144miR-625*miRNAHumanDownregulated in the HCC v/s non-tumor (with fold change 0.23) DiagnosticNormal v/s HCC/HCV/HBV p < 0.01Tissue23205106
2145miR-1228miRNAHumanDownregulated in the HCC v/s non-tumor (with fold change 0.30) DiagnosticNormal v/s HCC/HCV/HBV p < 0.01Tissue23205106
2146miR-1249miRNAHumanDownregulated in the HCC v/s non-tumor (with fold change 0.20) DiagnosticNormal v/s HCC/HCV/HBV p < 0.001Tissue23205106
2147miR-2116*miRNAHumanDownregulated in the HCC v/s non-tumor (with fold change 0.048) DiagnosticNormal v/s HCC/HCV/HBV p < 0.05Tissue23205106
2148miR-129*miRNAHumanDownregulated in the HCC v/s non-tumor DiagnosticNormal vs HCC, liver cancer p < 0.05Tissue23205106
2149miR-146b-3pmiRNAHumanDownregulated in the HCC v/s non-tumor DiagnosticNormal vs HCC, liver cancer p < 0.05Tissue23205106
2150miR-448miRNAHumanDownregulated in the HCC v/s non-tumor DiagnosticNormal vs HCC, liver cancer p < 0.05Tissue23205106
2160miR-515-3pmiRNAHumanUpregulated in HCC PrognosticHCC v/s other liver disease (cirrhosis/dysplasia); predict survival and recurrence of patients p < 0.01Tissue22429613
2161miR-518a-3pmiRNAHumanUpregulated in HCC PrognosticHCC v/s other liver disease (cirrhosis/dysplasia); predict survival and recurrence of patients p < 0.01Tissue22429613
2162miR-520fmiRNAHumanUpregulated in HCC PrognosticHCC v/s other liver disease (cirrhosis/dysplasia); predict survival and recurrence of patients p < 0.01Tissue22429613
2163miR-525-3pmiRNAHumanUpregulated in HCC PrognosticHCC v/s other liver disease (cirrhosis/dysplasia); predict survival and recurrence of patients p < 0.01Tissue22429613
2167CORO1CProteinHumanUpregulated in liver cancer tissues of HCCLM9-nude mice with spontaneous pulmonary metastasis and higher coronin-1C expression had more advanced stage in patients PrognosticAgressive or advanced-stage HCC v/s less-aggressive HCC; predict metastatic stage p < 0.05Tissue and Cells 20181269
2178miR-122miRNAHumanvariable expression between different hepatoma cell lines: PLC/PRF/5, Huh-1, and Hep40 exhibited very high levels of miR-122, whereas others, such as Hep3B and HepG2, expressed little or did not express miR-122 at all (e.g. SNU387, and SNU398) ; in HCC patients miR-122 was specifically repressed in Diagnostic and PrognosticNormal vs HCC; associated with survival, tumor size and differentiation status p < 0.001Tissue and Cells 19617899
2180circCDK13circRNAsHumanSuppressed expression in liver cancer DiagnosticNormal cell line vs cancer cell line p < 0.05Tissue29658568
2199MTHFRRNAsHumanMTHFR polymorphism was associated with HCC occurrence PrognosticNormal vs HCC; predict recurrence in patients p < 0.05Tissue29185200
2208SULT1A3/4ProteinHumanUpregulated in HCC PrognosticHCC v/s Normal; associated with metastatsis of patients p < 0.01Tissue29025375
2209ITGA2ProteinHumanUpregulated in HCC DiagnosticHBV-associated HCC v/s healthy/non-tumor/cirrhosis p < 0.0001Tissue28947976
2210BMP4ProteinHumanUpregulated in HCC DiagnosticHBV-associated HCC v/s healthy/non-tumor/cirrhosis p < 0.0001Tissue28947976
2211PLCB1ProteinHumanUpregulated in HCC DiagnosticHBV-associated HCC v/s healthy/non-tumor/cirrhosis p < 0.0001Tissue28947976
2212KDM6BProteinHumanDownregulated in HCC DiagnosticHBV-associated HCC v/s healthy/non-tumor/cirrhosis p < 0.0001Tissue28947976
2213MYCProteinHumanDownregulated in HCC DiagnosticHBV-associated HCC v/s healthy/non-tumor/cirrhosis p < 0.0001Tissue28947976
2214ITGA2ProteinHumanUpregulated in HCC DiagnosticHCV-associated HCC v/s healthy/non-tumor/cirrhosis p < 0.01Tissue28947976
2215BMP4ProteinHumanUpregulated in HCC DiagnosticHCV-associated HCC v/s healthy/non-tumor/cirrhosis p < 0.01Tissue28947976
2216PLCB1ProteinHumanUpregulated in HCC DiagnosticHCV-associated HCC v/s healthy/non-tumor/cirrhosis p < 0.01Tissue28947976
2217KDM6BProteinHumanDownregulated in HCC DiagnosticHCV-associated HCC v/s healthy/non-tumor/cirrhosis p < 0.001Tissue28947976
2218MYCProteinHumanDownregulated in HCC DiagnosticHCV-associated HCC v/s healthy/non-tumor/cirrhosis p < 0.0001Tissue28947976

         Raghava's group    CancerCSP    CancerSPP    CancerPDF    CancerTSP    CancerLSP    HCCPred   

Scroll to Top